New shot targets dangerous liver fat
NCT ID NCT07024212
Summary
This study is testing an investigational injection called DR10624 to see if it can reduce liver fat and scarring in people with metabolic fatty liver disease (MASLD) who are at high risk. About 110 participants will receive either the drug or a placebo for 12 weeks, with researchers measuring changes in liver fat using MRI scans. The main goal is to see if the injection safely reduces liver fat content compared to a dummy treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASLD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanjing Gulou Hospital
Nanjing, China
-
Prince of Wales Hospital, The Chinese University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
-
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, Zhejiang, China
-
The First Hospital of Jilin University
Changchun, China
Conditions
Explore the condition pages connected to this study.